secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2026-03-25T23:59:59+00:00
Accession:  0001493152-26-012673
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyadic reports FY 2025 net loss of $7.36M; revenue down to $3.09M
-----------------------------------------------------------------

- Cash and securities of $8.59M as of Dec 31, 2025, down from $9.29M a year earlier.
- Revenue fell to $3.09M from $3.50M; net loss widened to $7.36M ($0.23/sh) from $5.81M ($0.20/sh).
- Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant; Dyadic eligible for profit share.
- Expanded Fermbox Bio collaboration; commercial launch of recombinant DNase I (RNase-free).
- OEM distribution agreement with IBT Bioservices for DNase I and transferrin; BRIG Bio deal for alpha-lactalbumin.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000149315226012673/0001493152-26-012673-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000149315226012673/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-012673

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer